Baseline and early functional immune response is associated with subsequent clinical outcomes of PD-1 inhibition therapy in metastatic melanoma patients.
Alexandre GérardJerome DoyenMarion CremoniLaurent BaillyKevin ZorziCaroline Ruetsch-ChelliVesna BrglezAlexandra Picard-GauciLaura TroinVincent L M EsnaultThierry PasseronHenri MontaudiéBarbara Seitz-PolskiPublished in: Journal for immunotherapy of cancer (2021)
Our findings indicate that cytokine levels after in vitro non-specific stimulation could be a promising biomarker to predict the outcome of PD-1 inhibition therapy.